Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H13ClN2O.ClH |
Molecular Weight | 321.201 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.OC1(N2CCN=C2C3=CC=CC=C13)C4=CC=C(Cl)C=C4
InChI
InChIKey=NIUFFPYONFMTAH-UHFFFAOYSA-N
InChI=1S/C16H13ClN2O.ClH/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16;/h1-8,20H,9-10H2;1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C16H13ClN2O |
Molecular Weight | 284.74 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Mazindol is an amphetamine-like medicine which was developed by Sandoz in 1967 and approved by FDA for the treatment of obesity and Duchenne muscular dystrophy under the names Sanorex and Mazanor. The exact mechanism of action is unknown, but possibly involves the stimulation of beta-adrenergic receptors and inhibition of monoamine reuptake. Both Sanorex and Mazanor were withdrawn from the market by reason other than safety. NLS Pharma now is developing mazindol for Attention Hyperactivity Disorder in adults (phase II).
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.09 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27066959/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MAZINDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
35.63 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27066959/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MAZINDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.66 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27066959/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MAZINDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity. | 1976 |
|
Decreased densities of dopamine and serotonin transporters and of vesicular monoamine transporter 2 in severely kainic acid lesioned subregions of the striatum. | 2001 |
|
Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. | 2001 Aug 13-27 |
|
The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. | 2001 Aug 3 |
|
Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs. | 2001 Jul 1 |
|
Differential sensitivity to NaCl for inhibitors and substrates that recognize mutually exclusive binding sites on the neuronal transporter of dopamine in rat striatal membranes. | 2001 Mar |
|
Role of 5-HT(2a) and 5-HT(2B/2C) receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors. | 2001 Mar |
|
Effects of dopaminergic and cholinergic interactions on rat behavior. | 2001 Oct 5 |
|
5-HT3 receptor antagonist MDL 72222 attenuates cocaine- and mazindol-, but not methylphenidate-induced neurochemical and behavioral effects in the rat. | 2002 Feb |
|
Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. | 2002 Jul 1 |
|
1-Methyl-4-phenylpridinium (MPP+)-induced functional run-down of GABA(A) receptor-mediated currents in acutely dissociated dopaminergic neurons. | 2002 Oct |
|
Three-dimensional quantitative structure-activity relationships of mazindol analogues at the dopamine transporter. | 2002 Sep 12 |
|
Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter. | 2002 Sep 12 |
|
2,3-Disubstituted quinuclidines as a novel class of dopamine transporter inhibitors. | 2003 Mar 20 |
|
Apparent opposite effects of tetrabenazine and reserpine on the toxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine on nigro-striatal dopaminergic neurons. | 2003 Nov 7 |
|
Destruction of midbrain dopaminergic neurons by using immunotoxin to dopamine transporter. | 2003 Oct |
|
Synergistic interaction between mazindol, an anorectic drug, and swim-stress on analgesic responses in the formalin test in mice. | 2004 Jan 23 |
|
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. | 2004 Jun |
|
Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism. | 2004 Nov |
|
Endothelin-1 inhibits the neuronal norepinephrine transporter in hearts of male rats. | 2005 Aug 1 |
|
The interaction of methylphenidate and benztropine with the dopamine transporter is different than other substrates and ligands. | 2005 Aug 1 |
|
Dysfunction of the cortico-basal ganglia-cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism. | 2005 Dec |
|
Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters. | 2005 Jul |
|
Obesity. | 2005 Jun |
|
Effects of monoamine reuptake inhibitors on wet-dog shakes mediated by 5-HT2A receptors in ACTH-treated rats. | 2005 May |
|
A reliable model of intravenous MDMA self-administration in naïve mice. | 2006 Jan |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: DOI: 10.1604/9780440235378, Catalano J., 'The Women's Pharmacy: An Essential Guide to What Women Should Know About Prescription Drugs' (2008), p.218, Retrieved from https://books.google.es/books?id=WueSNTyQq6sC&dq
The usual dose is 1 mg three times a day an hour before meals or 2 mg once a day an our before lunch.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:14:37 UTC 2023
by
admin
on
Sat Dec 16 10:14:37 UTC 2023
|
Record UNII |
TYC95TXB8Q
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
TYC95TXB8Q
Created by
admin on Sat Dec 16 10:14:38 UTC 2023 , Edited by admin on Sat Dec 16 10:14:38 UTC 2023
|
PRIMARY | |||
|
DTXSID60974091
Created by
admin on Sat Dec 16 10:14:38 UTC 2023 , Edited by admin on Sat Dec 16 10:14:38 UTC 2023
|
PRIMARY | |||
|
26859-70-1
Created by
admin on Sat Dec 16 10:14:38 UTC 2023 , Edited by admin on Sat Dec 16 10:14:38 UTC 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
3041799
Created by
admin on Sat Dec 16 10:14:38 UTC 2023 , Edited by admin on Sat Dec 16 10:14:38 UTC 2023
|
PRIMARY | |||
|
DBSALT002359
Created by
admin on Sat Dec 16 10:14:38 UTC 2023 , Edited by admin on Sat Dec 16 10:14:38 UTC 2023
|
PRIMARY | |||
|
58535-70-9
Created by
admin on Sat Dec 16 10:14:38 UTC 2023 , Edited by admin on Sat Dec 16 10:14:38 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
PARENT -> SALT/SOLVATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |